Observational studyLipids in health and disease2025
Effects of remnant cholesterol on adverse renal outcomes in lupus nephritis.
Observational study in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundRemnant cholesterol (RC) causes inflammation and promotes kidney diseases development. However, its role in lupus nephritis (LN) remains unclear. The purpose of this study was to investigate the association between RC and LN.
methodsThis observational study was conducted among patients enrolled between 2000 and 2018 in the High Quality Evidence of Guangzhou Lupus Nephritis Cohort. The study outcomes were defined as adverse renal outcomes, including serum creatinine doubled and end-stage renal disease. Patients were stratified into lower and higher RC groups based on the optimal cutoff RC value (86.88 mg/dL) for adverse renal outcomes. To explore the association between renal outcomes and RC, survival analyses, multivariate Cox regression analyses, and subgroup analyses were conducted.
resultsOverall, 909 individuals were enrolled. Over a median follow-up of 8.33 (interquartile range, 3.08-12.83) years, 134(14.74%) of them reached renal endpoints. Kaplan-Meier survival analyses indicated that patients with higher RC levels were more susceptible to adverse renal outcomes in LN (P < 0.001). After adjusting for confounding factors, higher RC levels exhibited significant correlations with adverse renal outcomes in LN [hazard ratio (HR):1.98, 95% confidence interval (CI):1.16-3.39; P = 0.012]. Subgroup analyses revealed a strong relationship between the higher RC and adverse renal outcomes, particularly in patients aged < 40 years, with an estimated glomerular filtration rate < 60 ml/min/1.73m
conclusionsHigher RC levels were significantly associated with poor renal outcomes in LN, indicating that RC may become a non-invasive prognostic tool in clinical assessment of LN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.